Every 8-K that UFP Technologies Inc (UFPT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow UFPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UFPT filings page.
UFP Technologies, Inc. (UFPT) furnished updated investor presentation materials describing its MedTech-focused contract development and manufacturing business and multi-year performance. The company positions itself as a partner for medical device and sterile packaging solutions, serving large OEMs, niche device makers, and start-ups across six countries with more than 5,000 team members.
The presentation highlights revenue of $603 million in 2025, up from $179 million in 2020, with a reported 3.4× revenue growth over that period. Adjusted operating margin is shown rising from 10.0% in 2020 to 17.1% in 2025, and the company reports 29.0% gross margin and 17.2% adjusted operating margin year-to-date through June 30, 2026. As of August 17, 2026, the presentation states a market capitalization of approximately $2.5 billion.
Management outlines 3–5 year financial targets of 12–18% annual revenue growth, 28–31% gross margins, and 17–20% adjusted operating margins, supported by an organic growth and customer-centric M&A strategy focused on higher-growth medical segments such as robotic assisted surgery, infection control, cardiovascular, and wound care.
UFP Technologies, Inc. reported record second-quarter 2026 results, with net sales of $174.0 million, up 15.1% from a year earlier, and net income of $20.9 million, 21.4% higher than the 2025 period. GAAP diluted EPS was $2.68 and adjusted diluted EPS was $2.92.
Gross margin improved to 29.3%, while operating income rose 15.5% to $28.1 million and adjusted EBITDA increased 14.3% to $36.4 million. Organic sales growth was 12.4% for the quarter. Year-to-date, sales reached $328.2 million and net income $38.3 million, with adjusted EPS of $5.39.
At June 30, 2026, total assets were $681.9 million and total equity $462.4 million. Long-term debt excluding current installments was $104.8 million, and cash and cash equivalents were $9.0 million. Management noted strong MedTech growth, flat non-medical revenue, and continued investment in Dominican Republic operations.
UFP Technologies reported several leadership and compensation changes. The company appointed Ryan Stafford as General Counsel, Senior Vice President of Human Resources, and Secretary effective June 4, 2026, succeeding retiring executive Chris Litterio. Stafford joins with extensive public-company legal, HR, and M&A experience from Littelfuse and Tyco.
The Board also appointed Mitchell C. Rock as Chief Executive Officer and expanded the Board from seven to eight members, naming Rock to fill the new directorship. Under his offer letter, Stafford will receive a $400,000 base salary and a 2026 cash bonus opportunity targeted at 50% of salary, subject to performance.
The Compensation Committee approved equity awards under the 2003 Incentive Plan. Stafford received an annual equity grant valued at $650,000, split equally between restricted stock units (RSUs) and performance share awards. RSUs granted include 2,895 units for CEO Rock, 4,454 units for CFO Ronald J. Lataille, and 1,448 units for Stafford, generally vesting in thirds on March 1 of 2027, 2028, and 2029, except for Lataille’s separate schedule. Lataille’s 4,454 stock units represent $1 million, vesting 50% on June 5, 2028 and 50% on March 30, 2029, with continued vesting protection in certain termination scenarios.
Stafford’s performance share awards provide a target of 1,448 shares and a maximum of 2,896 shares based on operating income and return-on-invested-capital objectives, with determination expected in February 2029 and issuance on March 1, 2029, subject to employment and plan terms, including change-in-control provisions.
UFP Technologies, Inc. furnished updated investor presentation materials outlining its business, markets and financial profile. The company reports 2025 revenue of $603 million, up from $179 million in 2020, representing 3.4× revenue growth over that period.
For 2025, UFP cites a 28.6% gross margin and 17.1% adjusted operating margin, positioning itself within a large and growing global medical device market estimated at about $518 billion. Management targets 12–18% annual revenue growth, 28–31% gross margins and 17–20% adjusted operating margins over the next 3–5 years, and highlights a $1.7 billion market capitalization, non-GAAP metrics, and a strategy focused on high-margin MedTech segments and customer-centric acquisitions.
UFP Technologies, Inc. reported results of its June 4, 2026 Annual Meeting of Stockholders. Stockholders elected seven directors to serve until the 2027 annual meeting, including Symeria Hudson with 6,591,509 votes for and 87,556 votes withheld, with 423,120 broker non-votes recorded for each nominee.
Stockholders also approved, on a non-binding advisory basis, the Company’s executive compensation, with 5,971,694 votes for, 664,037 against, 43,334 abstentions and 423,120 broker non-votes. In addition, they ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026, with 7,029,294 votes for, 69,957 against and 2,934 abstentions.
UFP Technologies, Inc. disclosed that its General Counsel, Secretary, and Senior Vice President of Human Resources, Christopher P. Litterio, plans to retire from the company after a transition period. The filing indicates a planned leadership change in the company’s legal and human resources functions rather than an immediate departure.
UFP Technologies reported modestly higher results for the first quarter ended March 31, 2026. Net sales reached $154.2 million, up 4.1% from $148.1 million a year earlier, while net income rose 1.8% to $17.5 million.
GAAP diluted EPS was $2.24 and adjusted diluted EPS was $2.48, compared with $2.21 and $2.47 in 2025. Medical market sales grew 5.9% to $143.4 million, but non-medical sales fell 15.0% to $10.8 million, reflecting the company’s focus on MedTech.
Gross margin edged up to 28.8%, while SG&A increased to $21.0 million, or 13.6% of sales. Operating income was $23.4 million, and adjusted EBITDA improved to $31.0 million. Management highlighted growth in robotic surgery and patient support segments and plans to add two new facilities in the Dominican Republic to meet forecasted demand.
UFP Technologies has provided an updated investor presentation outlining its MedTech-focused contract manufacturing business, strategy, and financial targets. The company reports annual revenue of $603 million, with about 92% coming from medical technology customers and a market capitalization of roughly $1.7 billion as of February 26, 2026.
The presentation highlights exposure to a $550 billion global medical device market growing around 6%, and a $101 billion medical device CDMO market growing near 10%. Management targets 12–18% revenue growth, 28–31% gross margin, and 17–20% adjusted operating margin over three to five years. Historical gross margins increased from 24.9% in 2020 to 29.1% in 2024, while adjusted operating margin rose from 10.3% to 18.3% over the same period, before measuring 17.1% in 2025.
The materials also show a long-term stock price increase of 9,340% over 20 years through February 12, 2026, and describe a two-pronged growth strategy combining organic expansion in high-growth MedTech niches with acquisitions designed to be accretive within the first year.
UFP Technologies, Inc. has amended its long-term Manufacturing Supply Agreement with strategic medical customer Intuitive Surgical SARL. Through a wholly owned subsidiary, the company entered into Amendment No. 27, effective January 1, 2026.
The amendment extends the agreement’s term by two years through December 31, 2029, materially increases annual minimum volumes for the largest program in 2028 and 2029, adds an additional program, and introduces volume-based pricing tied to minimum purchase thresholds and cost-sharing provisions.
UFP Technologies, Inc. reported a material cybersecurity incident affecting many of its information technology systems, including functions such as billing and label making for customer deliveries. The company detected suspicious activity on or about February 14, 2026 and engaged external cybersecurity advisors to investigate.
UFP Technologies isolated affected systems, removed the third party from its IT environment, and restored access to impacted information in all material respects. Certain company or company-related data appears to have been stolen or destroyed, and some files were exfiltrated. The company is still determining whether sensitive or personal information was involved.
Operations have continued in all material respects, supported by contingency plans and data backups. The company expects a significant portion of direct response costs to be reimbursed through insurance and states that, as of this report, the incident has not had a material impact on its financial systems, operations, or financial condition, nor is it believed reasonably likely to do so.
UFP Technologies reported record 2025 results, with net income of $68.3 million, up 15.8% from 2024, and net sales of $602.8 million, a 19.5% increase. GAAP diluted EPS rose to $8.75, while adjusted EPS reached $9.76.
Growth was driven by a 23.2% increase in medical-market sales to $555.3 million, while non-medical sales fell 11.5% to $47.5 million. Organic sales growth for 2025 was 1.5%, reflecting a significant contribution from acquisitions.
Gross margin slipped to 28.3% from 29.1%, pressured by about $6.3 million of labor-related inefficiencies at the AJR facility. Even so, operating income climbed 14.1% to $92.3 million, adjusted EBITDA increased to $121.1 million, and long-term debt declined from $176.9 million to $123.0 million, strengthening the balance sheet.
UFP Technologies outlined compensation changes tied to its leadership transition and 2026 incentive programs. The board confirmed an Employment Offer Letter for Mitchell C. Rock, who becomes Chief Executive Officer on June 4, 2026, with a $700,000 base salary, an annual bonus opportunity up to 100% of salary, and long‑term incentive awards in restricted stock units.
Rock will receive a one‑time $650,000 RSU grant and, beginning in 2027, will be eligible for annual LTI awards targeted at up to $3,000,000 in RSUs. His severance agreement provides 18 months of base salary and COBRA reimbursement if terminated without cause or for good reason, and enhanced cash and full equity vesting upon a qualifying change of control.
The Compensation Committee also raised 2026 base salaries for senior executives and granted stock unit and performance share awards with multi‑year vesting and performance conditions. Outgoing CEO R. Jeffrey Bailly received 19,061 stock units, described as $5.1 million in value, vesting in 2027, along with a 2026 performance bonus plan and continued equity protections under his existing agreement.
UFP Technologies (UFPT) reported that it issued a press release announcing financial results for the third quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 to this Form 8-K.
The company states that the information under Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. The release includes forward-looking statements and a related cautionary note. UFPT’s common stock trades on The NASDAQ Stock Market L.L.C. under the symbol UFPT.
UFP Technologies, Inc. filed a Form 8-K to furnish updated investor presentation materials under Regulation FD. The company attached the revised presentation as Exhibit 99.1, which it plans to use in meetings with investors, other interested parties, and in various speaking engagements. The materials are designated as furnished, not filed, meaning they are not subject to certain Exchange Act liabilities or automatically incorporated into other SEC filings. The company also notes that the presentation includes forward-looking statements and directs readers to the cautionary language in the slides regarding risks and uncertainties that could cause actual results to differ.